재택 주입 요법 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 지역별, 부문 예측(2025-2030년)

Home Infusion Therapy Market Size, Share & Trends Analysis Report By Type (Product, Services), By Application (Anti-Infective, Endocrinology, Hydration Therapy, Chemotherapy), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,326,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,725,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,524,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

재택 주입 요법 시장 요약

세계 재택 주입 요법 시장은 2024년에 386억 6,000만 달러로 평가되었으며, 2025년부터 2030년까지 연평균 8.2% 성장하여 2030년에는 617억 2,000만 달러에 달할 것으로 예측됩니다. 재택 수액요법에서는 치료, 투약, 수액을 정맥주입을 통해 환자의 혈류에 직접 주입합니다.

이 시장의 성장은 운동 능력 저하를 특징으로 하는 노령 인구 증가, 재택 간호에 대한 선호도 증가, 기술 발전의 빠른 진화 등 몇 가지 중요한 요인에 의해 주도되고 있습니다. 수액요법은 정맥주사, 정맥수액요법 등의 중요한 구성요소를 포함하고 있으며, 면역 결핍, 암, 울혈성 심부전 등 경구용 약물이 효과적인 치료옵션이 되지 않는 증상에 대응하는 데 중요한 역할을 하고 있습니다. 이러한 치료에 대한 수요 증가는 환자의 장기 치료의 필요성에 기인하며, 재택 주입 요법은 병원 치료의 대안으로 비용 효율적인 치료법으로 주목받고 있습니다. 정맥주사 요법과 정맥 주입 요법을 도입하는 것이 원동력이 되어 환자는 집에서 편안하게 효과적이고 개별화된 의료 솔루션을 쉽게 이용할 수 있습니다.

재택 주입 요법의 비용 효율성은 전 세계 의료 시스템에서 채택을 촉진하는 주요 요인으로 작용하고 있습니다. 병원 밖에서 정맥주사 치료를 가능하게 함으로써 입원, 재입원, 장기입원 등 입원치료에 따른 비용을 대폭 절감할 수 있습니다. 이 모델에서는 직접적인 치료비가 절감되고, 시설 제반 비용과 직원 인건비 등 부수적인 지출도 최소화할 수 있습니다. 재택 주입 요법은 기존 입원 치료에 비해 비용을 크게 절감할 수 있어 환자와 의료비 지불자에게 매력적인 선택이 되고 있습니다. 예를 들어, 미국 재택수액협회(NHIA)에 따르면, 재택수액요법 비용은 하루 약 122-225달러입니다. 한편, 입원 치료의 경우 치료 내용에 따라 1일당 586-798달러가 소요됩니다.

마비, 골관절염, 당뇨병 등의 증상으로 운동능력 저하를 겪는 베이비붐 세대 인구가 증가함에 따라 재택 수액요법에 대한 수요가 확대될 것으로 예측됩니다. 입원 기간 단축이 시급한 것도 시장 성장에 크게 기여하는 중요한 요인입니다. 주목할 만한 점은 아포몰핀 피하 지속주사 요법이 파킨슨병(PD)에 매우 효과적인 치료법이라는 점이며, 피하 전달을 통한 PD 관리를 위해 다양한 제형들이 이용 가능하다는 점입니다. PD의 부담 증가에 대응하기 위해 피하주사 요법에 대한 수요가 눈에 띄게 급증하고 있습니다. 예를 들어, 파킨슨병 재단의 2022년 데이터 업데이트에 따르면, 미국에서는 매년 약 9만 명이 PD 진단을 받고 있습니다. 또한, 미국에서는 2030년까지 PD 환자 수가 120만 명 가까이 급증할 것으로 예측되고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 재택 주입 요법 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 재택 주입 요법 시장 분석 툴
  • 업계 분석 - Porter의 Five Forces 분석
  • PESTEL 분석

제4장 재택 주입 요법 시장 : 유형별 추정 및 동향 분석

• 유형별 부문 대시보드
• 재택 주입 요법 시장 변동 분석 : 유형별
• 세계의 재택 주입 요법 시장 규모와 동향 분석 : 유형별, 2018년-2030년
• 제품
  • 주입 펌프
  • 엘라스토머
  • 전기 기계
  • 중력
  • 기타
  • 정맥내 세트
  • IV 캐뉼라
  • 무바늘 커넥터
• 서비스

제5장 재택 주입 요법 시장 : 용도별 추정 및 동향 분석

• 용도별 부문 대시보드
• 재택 주입 요법 시장 변동 분석 : 용도별
• 세계의 재택 주입 요법 시장 규모와 동향 분석 : 용도별, 2018년-2030년
• 항감염
• 내분비학
  • 당뇨병
  • 기타
• 수분 보급 요법
  • 애슬리트
  • 기타
• 화학요법
• 경장영양
• 경장영양
• 전문의약품
• 기타

제6장 재택 주입 요법 시장 : 지역별 추정 및 동향 분석

• 지역별 시장 대시보드
• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역별 연속 바이오프로세스 시장 : 주요 포인트
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 네덜란드
  • 벨기에
  • 스위스
  • 러시아
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 인도네시아
  • 말레이시아
  • 싱가포르
  • 태국
  • 필리핀
• 라틴아메리카
  • 브라질
  • 아르헨티나
  • 콜롬비아
  • 칠레
• 중동 및 아프리카(MEA)
  • 아르헨티나
  • 남아프리카공화국
  • 남아프리카 라비아
  • 아랍에미리트(UAE)
  • 이스라엘
  • 이집트

제7장 경쟁 구도

• 주요 시장 진출기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 구도
  • 주요 기업 히트맵 분석, 2024년
• 기업 개요
  • Baxter
  • B. Braun SE
  • BD
  • Fresenius Kabi AG
  • ICU Medical, Inc.
  • Terumo Corporation
  • JMS Co. Ltd.
  • Option Care Health, Inc.
  • CareCentrix, Inc.
  • Coram LLC.
  • PharMerica Corporation
  • Moog Inc.
  • Amedisys, Inc.

LSH

영문 목차

영문목차

Home Infusion Therapy Market Summary

The global home infusion therapy market was valued at USD 38.66 billion in 2024 and is expected to reach USD 61.72 billion by 2030, growing at a CAGR of 8.2% from 2025 to 2030. Home infusion therapy involves delivering treatments, medications, or fluids directly into a patient's bloodstream through intravenous (IV) infusion, usually in the comfort and convenience of their home.

The market's growth is driven by several key factors, including the expanding geriatric population characterized by decreased mobility, a rising preference for home care, and the swift evolution of technological advancements. Infusion therapy, encompassing essential components like IV therapy and IV hydration therapy, plays a crucial role in addressing conditions such as immune deficiencies, cancer, and congestive heart failure, where oral medication is not a viable treatment option. The increasing demand for these therapies stems from the need for long-term treatment among patients, positioning home infusion therapy as a notably cost-effective alternative to hospital-based care. Incorporating IV therapy and IV hydration therapy serves as a driving force, providing patients with enhanced accessibility to effective and personalized medical solutions in the comfort of their homes.

The cost-effectiveness of home infusion therapy is a major factor driving its adoption across global healthcare systems. Enabling IV treatments outside hospital settings significantly reduces expenses associated with inpatient care, including hospital admissions, re-admissions, and extended stays. This model lowers direct treatment costs and minimizes ancillary expenditures such as facility overhead and staffing. Home infusion therapy offers substantial cost savings compared to traditional inpatient care, making it an attractive option for patients and healthcare payers. For instance,according to the National Home Infusion Association (NHIA), home infusion therapy costs approximately USD 122 to USD 225 per day. In contrast, inpatient care can range from USD 586 to USD 798 per day, depending on the therapy administered.

The increasing demographic of baby boomers struggling with diminished mobility due to conditions such as paralysis, osteoarthritis, and diabetes is expected to amplify the demand for home infusion therapy. The growing imperative to reduce the duration of inpatient stays is a pivotal factor poised to contribute significantly to the market's growth. Remarkably, continuous subcutaneous (SC) apomorphine infusion emerges as an exceptionally effective treatment for Parkinson's disease (PD), with diverse drug formulations available for the management of PD through subcutaneous delivery. In response to the mounting burden of PD, there is a notable surge in the demand for subcutaneous infusion therapy. For instance, in line with the Parkinson's Foundation's 2022 data update, approximately 90,000 individuals receive a PD diagnosis annually in the U.S. Furthermore, the anticipated number of people living with PD in the country is projected to soar to nearly 1.2 million by the year 2030.

Global Home Infusion Therapy Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels as well as provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the home infusion therapy market report on the basis of type, application, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Product
  • Infusion Pumps
  • Elastomeric
  • Electromechanical
  • Gravity
  • Others
  • Intravenous Sets
  • IV Cannulas
  • Needleless Connectors
• Services
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Anti-Infective
• Endocrinology
  • Diabetes
  • Others
• Hydration Therapy
  • Athlete
  • Others
• Chemotherapy
• Enteral Nutrition
• Parenteral Nutrition
• Specialty Pharmaceuticals
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Switzerland
  • Russia
  • Sweden
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Malaysia
  • Singapore
  • Thailand
  • Philippines
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Rest of Latin America
• Middle East & Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Egypt
  • Rest of Middle East & Africa (MEA)

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type Outlook
  • 2.2.2. Application Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Home Infusion Therapy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Home Infusion Therapy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Home Infusion Therapy Market: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. Home Infusion Therapy Market: Type Movement Analysis
• 4.3. Global Home Infusion Therapy Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Million)
• 4.4. Product
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Infusion Pumps
    • 4.4.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Elastomeric
    • 4.4.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Electromechanical
    • 4.4.4.1.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Gravity
    • 4.4.5.1.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.7. Intravenous Sets
    • 4.4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.8. IV Cannulas
    • 4.4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.4.9. Needleless Connectors
• 4.5. Services
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Home Infusion Therapy Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Home Infusion Therapy Market: Application Movement Analysis
• 5.3. Global Home Infusion Therapy Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Anti-Infective
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Endocrinology
  • 5.5.1. Diabetes
    • 5.5.1.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Others
    • 5.5.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.3. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.6. Hydration Therapy
  • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Athlete
    • 5.6.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6.3. Others
    • 5.6.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.7. Chemotherapy
  • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.8. Enteral Nutrition
  • 5.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.9. Parenteral Nutrition
  • 5.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.10. Specialty Pharmaceuticals
  • 5.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.11. Others
  • 5.11.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Home Infusion Therapy Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Continuous Bioprocessing Market By Region: Key Takeaways
• 6.4. North America
  • 6.4.1. U.S.
    • 6.4.1.1. Key Country Dynamics
    • 6.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.1.3. Competitive Scenario
    • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Canada
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.2.3. Competitive Scenario
    • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Mexico
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.3.3. Competitive Scenario
    • 6.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. UK
    • 6.5.1.1. Key Country Dynamics
    • 6.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.1.3. Competitive Scenario
    • 6.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Germany
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.2.3. Competitive Scenario
    • 6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.3. France
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.3.3. Competitive Scenario
    • 6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Italy
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.4.3. Competitive Scenario
    • 6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.5.3. Competitive Scenario
    • 6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Netherlands
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.6.3. Competitive Scenario
    • 6.5.6.4. Netherlands Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Belgium
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.7.3. Competitive Scenario
    • 6.5.7.4. Belgium Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.8. Switzerland
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.8.3. Competitive Scenario
    • 6.5.8.4. Switzerland Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.9. Russia
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.9.3. Competitive Scenario
    • 6.5.9.4. Russia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.10. Sweden
    • 6.5.10.1. Key Country Dynamics
    • 6.5.10.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.10.3. Competitive Scenario
    • 6.5.10.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key Country Dynamics
    • 6.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.1.3. Competitive Scenario
    • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.2.3. Competitive Scenario
    • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.3. India
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.3.3. Competitive Scenario
    • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.4. South Korea
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.4.3. Competitive Scenario
    • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.5.3. Competitive Scenario
    • 6.6.5.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Indonesia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.6.3. Competitive Scenario
    • 6.6.6.4. Indonesia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Malaysia
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.7.3. Competitive Scenario
    • 6.6.7.4. Malaysia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Singapore
    • 6.6.8.1. Key Country Dynamics
    • 6.6.8.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.8.3. Competitive Scenario
    • 6.6.8.4. Singapore Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.9. Thailand
    • 6.6.9.1. Key Country Dynamics
    • 6.6.9.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.9.3. Competitive Scenario
    • 6.6.9.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.10. Philippines
    • 6.6.10.1. Key Country Dynamics
    • 6.6.10.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.10.3. Competitive Scenario
    • 6.6.10.4. Philippines Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1.1. Key Country Dynamics
  • 6.7.1.2. Regulatory Framework/ Reimbursement Structure
  • 6.7.1.3. Competitive Scenario
  • 6.7.1.4. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.2.3. Competitive Scenario
    • 6.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.3.3. Competitive Scenario
    • 6.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Colombia
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.4.3. Competitive Scenario
    • 6.7.4.4. Colombia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.5. Chile
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.5.3. Competitive Scenario
    • 6.7.5.4. Chile Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.8. Middle East & Africa (MEA)
  • 6.8.1.1. Key Country Dynamics
  • 6.8.1.2. Regulatory Framework/ Reimbursement Structure
  • 6.8.1.3. Competitive Scenario
  • 6.8.1.4. Middle East & Africa (MEA)Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.2.3. Competitive Scenario
    • 6.8.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.3. South Africa
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.3.3. Competitive Scenario
    • 6.8.3.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.4. South Arabia
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.4.3. Competitive Scenario
    • 6.8.4.4. South Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.5. UAE
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.5.3. Competitive Scenario
    • 6.8.5.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.6. Israel
    • 6.8.6.1. Key Country Dynamics
    • 6.8.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.6.3. Competitive Scenario
    • 6.8.6.4. Israel Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.7. Egypt
    • 6.8.7.1. Key Country Dynamics
    • 6.8.7.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.7.3. Competitive Scenario
    • 6.8.7.4. Egypt Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key Company Heat Map Analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Baxter
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Type Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. B. Braun SE
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Type Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. BD
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Type Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Fresenius Kabi AG
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Type Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. ICU Medical, Inc.
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Type Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. Terumo Corporation
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Type Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. JMS Co. Ltd.
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Type Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. Option Care Health, Inc.
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Type Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. CareCentrix, Inc.
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Type Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Coram LLC.
    • 7.4.10.1. Company Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Type Benchmarking
    • 7.4.10.4. Strategic Initiatives
  • 7.4.11. PharMerica Corporation
    • 7.4.11.1. Company Overview
    • 7.4.11.2. Financial Performance
    • 7.4.11.3. Type Benchmarking
    • 7.4.11.4. Strategic Initiatives
  • 7.4.12. Moog Inc.
    • 7.4.12.1. Company Overview
    • 7.4.12.2. Financial Performance
    • 7.4.12.3. Type Benchmarking
    • 7.4.12.4. Strategic Initiatives
  • 7.4.13. Amedisys, Inc.
    • 7.4.13.1. Company Overview
    • 7.4.13.2. Financial Performance
    • 7.4.13.3. Type Benchmarking
    • 7.4.13.4. Strategic Initiatives

관련자료